10-Q/A: Cannabis Bioscience International Holdings Files Amended 10-Q, Reports Improved Financials

Cannabis Bioscience International Holdings files an amended 10-Q for the quarter ended November 30, 2024, showing improved revenue and reduced losses compared to the previous year.

Summary

• Cannabis Bioscience International Holdings has filed an amended quarterly report on Form 10-Q for the period ending November 30, 2024.
• The amendment was made to furnish interactive data files and correct minor errors in the notes to the financial statements.
• The company reported a net loss of $155,833 for the six months ended November 30, 2024, which is an improvement compared to a net loss of $306,217 for the same period in 2023.
• Revenue increased to $253,135 for the six months ended November 30, 2024, up from $136,569 in the same period of 2023, primarily due to growth in clinical trials and consulting fees.
• Operating loss decreased to $157,231 for the six months ended November 30, 2024, compared to $268,182 for the same period in 2023.
• The company's cash and cash equivalents stood at $1,002 as of November 30, 2024.
• The company has a negative working capital of $857,255 as of November 30, 2024.
• The company has an accumulated deficit of $5,489,913 as of November 30, 2024.
• The company's ability to continue as a going concern is dependent on raising additional capital and executing its business plan.

Sentiment

Score: 5

Explanation: The document shows some positive trends with increased revenue and reduced losses, but the company's financial position remains precarious with low cash reserves, negative working capital, and a significant accumulated deficit. The going concern risk is a major concern.

Positives

• The company experienced a significant increase in revenue, primarily driven by clinical trials and consulting fees.
• The company's net loss decreased substantially compared to the same period last year.
• Operating losses were reduced due to increased revenue and decreased operating expenses.
• The company recorded a gain from debt forgiveness, positively impacting the bottom line.

Negatives

• The company continues to operate with a negative working capital.
• The company has a significant accumulated deficit.
• The company's cash balance remains very low.
• The company is dependent on raising additional capital to continue as a going concern.
• The company has significant related party payables.

Risks

• The company's ability to continue as a going concern is uncertain and dependent on securing additional financing.
• The company has a history of recurring losses and negative cash flows from operations.
• The company's debt obligations are in arrears, and they are negotiating with lenders to reschedule payments.
• The company's financial statements do not include adjustments related to the recoverability of assets or the classification of liabilities should the company be unable to continue as a going concern.
• The company relies on a small number of customers for a significant portion of its revenue, creating a concentration risk.

Future Outlook

The company's ability to continue as a going concern depends on the successful execution of its operating plan, including expanding operations and raising debt or equity financing. There is no assurance that the company will be able to obtain such financing on satisfactory terms or at all.

Management Comments

• Management has evaluated all subsequent events when these consolidated financial statements were issued and has determined that none of them requires disclosure herein.
• The principal executive officer and the principal accounting officer concluded that these disclosure controls and procedures were not effective as of such date, at a reasonable level of assurance.

Industry Context

The company operates in the medical cannabis and clinical trials sectors, which are experiencing growth but also face regulatory and competitive challenges. The company's focus on education and clinical trials positions it to capitalize on the increasing acceptance of medical cannabis, but it must overcome its financial challenges to succeed.

Comparison to Industry Standards

• It is difficult to make a direct comparison to industry standards due to the unique combination of education and clinical trial services offered by Cannabis Bioscience International Holdings.
• Many cannabis companies focus on cultivation, processing, or retail, while this company is focused on education and clinical trials.
• The company's financial performance is significantly below that of established pharmaceutical companies conducting clinical trials.
• The company's negative working capital and accumulated deficit are concerning compared to industry benchmarks for companies in the biotechnology and pharmaceutical sectors.
• The company's reliance on a small number of customers is a risk not typically seen in larger, more diversified companies.

Management Changes

Related Party Transactions

• The company has significant related party payables for cash advances.
• The company entered into a loan agreement with related parties for $75,000.
• The company issued shares of common stock and preferred stock to related parties as compensation.
• The company leases office space from related parties.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern issues.
• Employees may be impacted by potential layoffs or restructuring if the company cannot secure additional funding.
• Customers may be affected by potential disruptions in service if the company faces financial difficulties.
• Creditors face the risk of non-payment due to the company's debt obligations and financial challenges.

Next Steps

• The company needs to secure additional financing to continue operations.
• The company needs to execute its business plan to increase revenue and reduce losses.
• The company needs to address its debt obligations and negotiate with lenders.

Key Dates

Keywords

Cannabis Bioscience International Holdings, Clinical Trials, Financial Results, 10-Q, Cannabinoids, Medical Cannabis, Going Concern, Revenue, Net Loss, Operating Loss, Debt, Equity, Related Party Transactions